On Wednesday, May 9, 2018 from 11:00 AM – 12:00 PM ET, a diabetes CME program about new long acting insulins for the treatment of Type 2 Diabetes will air live on DiabetesSeriesLive. New Long-acting Insulins for the Treatment of Type 2 Diabetes: Data, Guidelines, and Perspectives on Patient and Provider Barriers will cover:
• The pharmacokinetics and pharmacodynamics of the newer ultra-long basal insulins and how these differ from older formulations
• Indications for, methods to start or transition from analog basal insulin, and means to address adverse event concerns for ultra-long basal insulins to help achieve individualized patient treatment goals
• Potential patient, provider, and health care system barriers to initiation and titration of basal insulin treatment programs, particularly those using newer ultra-long basal insulins, and methods to overcome these barriers

After the live presentation, the program will be available for 6 months on demand, so clinicians can watch at any time is convenient in their busy schedules. Find this program and more diabetes CME on DiabetesSeriesLive.

The clinician program follows on the heels of an aligned education program for patients and caregivers which was presented live in March, 2018 and is now available on demand. 1 in 11 adults in the world has some form of diabetes; managing blood glucose levels can be a very difficult process for diabetic patients, and although insulin may become necessary to meet A1c goals, many patients are wary of starting it out. The new long-acting insulin options offer patients a brand-new way to help meet their target, and the tandem programs – for clinicians and patients, respectively – aim to demystify this option for patients and equip clinicians to provide the latest information. As both programs will track outcomes, we are looking forward to seeing how far these programs can move the needle on diabetes education.

The clinician program will include an interactive panel discussion, slide presentation, poll questions and more. The speakers for this live program include:
• Richard S. Beaser, M.D. – a practicing physician in the Joslin Clinic who holds the position of Associate Clinical Professor of Medicine at Harvard Medical School
• Alissa R. Segal, PharmD, RPh, CDE, CDTC, FCCP – an Associate Professor at MCPHS University and clinical pharmacist at the Joslin Diabetes Center
• Mark Molitch, M.D. – the Martha Leland Sherwin Professor of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine at the Northwestern University Feinberg School of Medicine.

For more information about the program or to save a seat – either to attend on live day or receive the on-demand version via email when it is released – head to DiabetesSeriesLive.

Want to learn more about how we’re leading the pack when it comes to educating patients and clinicians together on topics like diabetes, obesity, and more? Email us!